- Open Access
Suppression of STIM1 inhibits human glioblastoma cell proliferation and induces G0/G1 phase arrest
Journal of Experimental & Clinical Cancer Research volume 32, Article number: 20 (2013)
Depletion of calcium (Ca2+) from the endoplasmic reticulum (ER) activates the ubiquitous store-operated Ca2+ entry (SOCE) pathway which sustains long-term Ca2+ signals and is critical for cellular functions. Stromal interacting molecule 1 (STIM1) serves a dual role as an ER Ca2+ sensor and activator of SOCE. Aberrant expression of STIM1 could be observed in several human cancer cells. However, the role of STIM1 in regulating tumorigenesis of human glioblastoma still remains unclear.
Expression of STIM1 protein in a panel of human glioblastoma cell lines (U251, U87 and U373) in different transformation level were evaluated by Western blot method. STIM1 loss of function was performed on U251 cells, derived from grade IV astrocytomas-glioblastoma multiforme with a lentvirus-mediated short harpin RNA (shRNA) method. The biological impacts after knock down of STIM1 on glioblastoma cells were investigated in vitro and in vivo.
We discovered that STIM1 protein was expressed in U251, U87 and U373 cells, and especially higher in U251 cells. RNA interference efficiently downregulated the expression of STIM1 in U251 cells at both mRNA and protein levels. Specific downregulation of STIM1 inhibited U251 cell proliferation by inducing cell cycle arrest in G0/G1 phase through regulation of cell cycle-related genes, such as p21Waf1/Cip1, cyclin D1 and cyclin-dependent kinase 4 (CDK4), and the antiproliferative effect of STIM1 silencing was also observed in U251 glioma xenograft tumor model.
Our findings confirm STIM1 as a rational therapeutic target in human glioblastoma, and also indicate that lentivirus-mediated STIM1 silencing is a promising therapeutic strategy for human glioblastoma.
Human glioblastomas are the most common primary tumors of the central nervous system . Despite recent development had been found in surgical resection, radiotherapy and chemotherapy, the prognosis has not changed significantly over the past two decades with a mean survival of less than twelve months from the time of diagnosis . Therefore, new treatment strategies for glioblastomas is extremely needed. The increasing knowledge about genetic alterations that occur in glioblastomas has focused attention on development of targeted therapy which restore cell cycle or apoptosis defects in glioma cells. Therefore it could be an attractive alternative to conventional medicine [3–5].
Calcium (Ca2+) is a multifunctional messenger that control many cellular processes ranging from short-term responses such as muscle contraction and secretion to long-term regulation of cell growth and proliferation [6, 7]. Store-operated Ca2+ entry (SOCE) is a major mechanism for Ca2+ entry across the cell membrane, which is stimulated in response to depletion of Ca2+ from intracellular Ca2+ stores (primarily the endoplasmic reticulum (ER)) and mediated via the activation of specific plasma membrane channels, termed as store-operated channels (SOCs) . Stromal interacting molecule 1 (STIM1) is a highly conserved type-I membrane, ER-resident protein, containing a luminal EF-hand Ca2+-binding domain and several cytosolic protein-protein interaction domains, and serves a dual role as an ER Ca2+ sensor and activator of SOCE [9–11]. STIM1 initiates the process of store-operated Ca2+ influx by sensing the deletion of Ca2+ from the lumen of the ER store. It then migrates to the plasma membrane and forms aggregates at plasma membrane sites of Ca2+ entry and interacts either directly or in a complex with the plasma membrane-localized transmembrane protein Orai1 [9, 10].
The role of STIM1 in regulating cancer progression remains controversial. In early investigations which were performed prior to the discovery of its role in Ca2+ signaling, STIM1 was described as a tumor suppressor for it causes growth arrest in human G401 rhabdoid tumor cells and human RD rhabdomyosarcoma cells [12, 13]. However, subsequent studies revealed a potential role of STIM1 as an oncogene because it is up-regulated in several human cancers, such as breast cancer , glioblastoma [15, 16] and cervical cancer . Thus, more work needs to be done to fully determine the role of STIM1 in tumorigenesis which might vary in different tumor types. In the present study, we found that expression of STIM1 protein was higher in U251 and U87 glioblastoma multiforme (both Grade IV) lines than in U373 astrocytoma (Grade III), particularly higher in U251 cells . Thus, we applied lentivirus-mediated small interfering RNA (siRNA) to suppress STIM1 expression and investigated the effects of STIM1 knock down on cell proliferation and cell cycle progression in U251 cells. Additionally, the proliferation-related markers (p21Waf1/cip1, Cyclin D1 and CDK4) were assessed in U251 cells with loss of function of STIM1. As a proliferation inhibitor, p21Waf1/cip1 was chosen because it is poised to play an important role in preventing tumor development. Cyclin D1-CDK4 complexes promote G1 phase progression through phosphorylation and inactivation of the retinoblastoma (Rb) gene product. Our results showed that specific downregulation of STIM1 inhibited human glioblastoma cell proliferation and induced G0/G1 phase cell cycle arrest by increasing expression of p21Waf1/cip1 and decreasing expression of Cyclin D1-CDK4. Therefore, STIM1 may serve as a therapeutic target for human glioblastoma.
Reagents and antibodies
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), TRIzol® Reagent and Lipofectamine™ 2000 were purchased from Invitrogen (Carlsbad, CA); 3-(4,5-dimethylthylthiazol-2yl-)-2,5-diphenyl tetrazolium bromide (MTT) (Dingguo biology, Shanghai, China); Dimethylsulfoxide (DMSO) (Shanghai Sibas Biotechnology Development Co., Ltd., China); 5-Bromo-2-deoxyuridine (BrdU) Cell Proliferation ELISA kit was purchased from Roche Applied Sciences (Indianapolis, IN); Giemsa was purchased from Chemicon International (Temecula, CA); Propidium Iodide (PI) was purchased from Sigma-Aldrich (St. Louis, MO); Bicinchoninic acid (BCA) Protein assay was purchased from HyClone-Pierce (South Logan, UT); M-MLV Reverse Transcription was purchased from Promega (Madison, WI); Oligo-dT was purchased from Sangon Biotech (Shanghai, China); SYBR green Master Mixture was purchased from Takara (Otsu, Japan); pFH-L vector and virion-packaging elements (packing plasmid mix) were obtained from Holybiol (Shanghai, China). Mouse anti-STIM1, mouse anti-GAPDH, p21Waf1/Cip1, cyclin D1, cyclin-dependent kinase 4 (CDK4) and goat anti-mouse IgG were purchased from Santa Cruz biotechnology (Santa Cruz, CA), mouse anti-STIM2 was purchased from Abcam plc (Abcam, UK), mouse anti-Orai1 was purchased from Sigma biotechnology (Sigma- -Aldrich, US). All other chemicals were of analytical grade.
Human kidney cell line HEK293,human glioblastoma cell lines, U251, U87 and U373, were all obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM containing 10% FBS, 100U/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified atmosphere containing 5% CO2.
siRNA design and construction of recombinant lentiviral vector
Recombinant lentiviral vector was constructed as described previously . The candidate sequence (5′-CCTGGATGATGTAGATCATAA-3′) in the STIM1 cDNA sequence (GenBank accession number NM_003156) was selected for siRNA and blasted against the human genome database to eliminate cross-silence phenomenon with non-target genes. Scrambled siRNA (5′-TTCTCCGAACGTGTCACGT-3′) that does not target any genes was used as the negative control. Short hairpin RNA (shRNA) was constructed by annealing the synthetic DNA oligonucleotide primers, then naturally cooled to room temperature, and inserted between the NheI and PacI sites of lentiviral expression vector pFH-L which contains the green fluorescent protein (GFP) gene as a reporter with an internal CMV promoter. Clone identity was verified by sequencing.
Considering STIM1 CDS > 2 kb and inefficient expression of construct RESC lentiviral vector, another shRNA targeting the same gene STIM1 (NM_003156.3) was chosen to construct to get comparable results. The sense siRNA sequences were CGGCAGAAGCTGCAGCTGA and antisense siRNA sequences were TCAGCTGCAGCTTCTGCCG.
Recombinant lentiviral vector was produced by co-transfecting HEK293FT cells with lentiviral expression vector and packing plasmid mix using Lipofectamine™ 2000, according to the manufacturer’s instructions. Infectious lentiviral particles were harvested at 48 h post-transfection, centrifuged to get rid off cell debris, and then filtered through 0.45 μm cellulose acetate filters. The virus was concentrated by spinning at 4,000 g for 15 min following by a second spin (<1,000 g, 2 min). The titer of recombinant lentivirus was determined by serial dilution on 293 T cells.
Recombinant lentivirus transfection in U251 cells
For lentivirus transduction, U251 cells were subcultured at 5 × 104 cells/well into 6-well culture plates. After grown to 30% confluence, cells were transducted with STIM1-siRNA-expressing lentivirus (si-STIM1) or control-siRNA-expressing lentivirus (si-CTRL) at a multiplicity of infection (MOI) of 50. Cells were harvested at 72 h after infection and the transduction efficiency was evaluated by counting the percentage of GFP-positive cells.
Quantitative real-time RT-PCR analysis
Total RNA from infected cells was isolated using TRIzolReagent as recommended by the manufacturer. The quantity and purity of RNA were determined by UV absorbance spectroscopy. cDNA preparation was performed according to standard procedures using oligo-dT primer and M-MLV Reverse Transcriptase. Quantitative real-time PCR was performed by SYBR Green Master Mixture and analyzed on TAKARA TP800-Thermal Cycler Dice™ Real-Time System. The following primers were used for STIM1: 5′-AGCCTCAGCCATAGTCACAG-3′ (Forward), 5′-TTCCACATCCACATCACCATTG-3′ (Reverse); for p21Waf1/Cip1, 5′-GGGACAGCAGAGGAAGACC-3′ (Forward), 5′-GACTAAGGCAGAAGATGTAGAGC-3′ (Reverse); for cyclin D1, 5′-GGTGGCAAGAGTGTGGAG-3′ (Forward), 5′-CCTGGAAGTCAACGGTAGC-3′ (Reverse); for CDK4, 5′-GAGGCGACTGGAGGCTTTT-3′ (Forward), 5′-GGATGTGGCACAGACGTCC-3′ (Reverse). Housekeeping gene GAPDH was used as internal control and the primers are: 5′-AGGTCGGAGTCAACGGATTTG-3′ (Forward), 5′-GTGATGGCATGGACTGTGGT-3′ (Reverse). Thermal cycling conditions were subjected to 15 s at 95°C and 45 cycles of 5 s at 95°C and 30s at 60°C. Data was analyzed with TAKARA Thermal Dice Real Time System software Ver3.0. The gene expression change after lentivirus transduction was presented as relative expression (fold over the negative control or percentage of the negative control) after normalizing to GAPDH, and calculated using the 2-ΔΔCt method as described previously .
Western blot analysis
Lentivirus-transduced cells were washed twice with ice-cold PBS and suspended in a lysis buffer (2% Mercaptoethanol, 20% Glycerol, 4% SDS in 100 mM Tris-HCl buffer, pH 6.8). After 15 min of incubation on ice, cells were disrupted by ultrasound on ice. Total cell lysates were then centrifuged (12,000 g, 15 min, 4°C) and the supernatants were employed for further processing. The protein concentration was determined by BCA protein assay kit. Equal amount of proteins was loaded and separated by SDS-PAGE, and then transferred onto PVDF membrane (Schleicher&Schuell Co., Keene, NH) using an electro-blotting apparatus (Tanon, Shanghai, China). The membrane was blocked with 5% nonfat milk in TBST solution for 1 h at room temperature, and incubated overnight at 4°C with specific antibody to STIM1, p21Waf1/Cip1, STIM2, Orai1, cyclin D1 and CDK4 at the dilution 1:800, 1:1000, 1:800, 1:1000, 1:1500, and 1:1000, respectively. After three washes in TBST solution, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody diluted with TBST solution at room temperature for 2 h. The signals of detected proteins were visualized on ECL plus Western blotting detection system (Amersham Biosciences, Inc., Piscataway NJ). GAPDH protein levels were used as a loading control.
MTT cell viability assay and direct cell counting method
Cell viability was determined by a colorimetric MTT assay which described previously . Briefly, lentivirus-transduced or TRPC entryway paralysed cells were seeded in 96-well plates at a density of 2 × 103 cells/well. Ten microliters of MTT solution (5 mg/mL) was added into each well once daily for 5 days, and plates were incubated for 4 h at 37°C. After removal of the supernatant, 100 μL of DMSO was added to dissolve the crystals. The absorbance at 490 nm was detected with a microplate reader (Bio-Rad 680). Growth curve was performed according to the absorbance values (A) of 490 nm.
On the other hand, direct cell counting method was also used to cross-checking the results of MTT assay. Double target RNAi U251 cells were seeded in 96-well plates at a density of 1 × 104 cells/well. After that, number of cells at 24 h and 48 h after seeding would be counted by blood cell counting plate. Besides, we count 3 wells for reduce error every time point. Growth curve was made according to the average number of cells in 3 wells.
BrdU incorporation assay
Cell proliferation was also quantified by measuring BrdU incorporation during DNA synthesis using the BrdU Cell Proliferation ELISA kit. The experiment was performed according to the manufacturer’s protocol. Briefly, 10 μL/well of BrdU labeling solution was added to cells at 24 h and 72 h after culture. After overnight incubation, cells were fixed with 200 μL/well of fix solution for 30 min in the dark at room temperature, and then incubated with peroxidase-conjugated anti-BrdU antibody for 90 min in the dark at room temperature. A substrate solution was then added into each well, and absorbance was measured using microplate reader (Bio-Rad 680) at a wavelength of 450 nm with a reference wavelength of 630 nm. The number of proliferating cells is represented by the level of BrdU incorporation which directly correlates to the absorbance values. Growth rate (R) was calculated by the following equation:
where A72h and A24h indicate the absorbance at 450 nm after 24 and 72 hours of incubation.
Colony formation assay
Lentivirus-transduced glioblastoma cells (200 cells/ well) were seeded in 6-well plates. Culture medium was changed at regular time intervals. After 14 days of culture, adherent cells were washed twice with PBS, fixed with 4% paraformaldehyde for 30 min at room temperature. The colonies were stained with Giemsa solution for 15 min, then washed with water and air-dried. Cell colonies were counted using a light microscopy. The experiment was performed in triplicate.
Cell cycle analysis
The effect of STIM1 on cell cycle distribution was determined by flow cytometry . Briefly, lentivirus-transduced U251 cells (1 × 105 cells/dish) were seeded at 6-cm dishes. Cells were harvested when they reach 80% confluence, and fixed at least 1 h with 70% ice-cold ethanol at 4°C. Cells were washed with PBS and resuspended in 1 mL of PBS containing 50 μg/mL PI and 100 μg/mL RNase A. After following incubation for 1 h in the dark at room temperature, cells were analyzed by flow cytometry using a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA) at 24, 48 and 72 hrs after transduction. The fractions of cells in G0/G1, S, and G2/M phases were analyzed using dedicated software.
Xenograft tumor model
The antitumor effects of siSTIM1 were evaluated in viv o using the U251 human glioma xenograft model in nude mice. All animal procedures were performed according to the guidelines of Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences. Briefly, U251 cells were infected with si-STIM1-expressing lentivirus or control-siRNA-expressing lentivirus at MOI of 50. When an apparent efficiency of 80%-90% GFP-positive cells was observed, cells were harvested and suspended at a density of 2 × 107/mL DMEM (without serum), and 5 × 106 cells were subcutaneously injected into the right dorsal flank of male BALB/c nu/nu athymic nude mice (SLAC Laboratory Animal Co. Ltd., Shanghai, China, 4-6 week-old) (n = 10 per group). The mice were housed and maintained under specific-pathogen free (SPF) condition. Tumor size was measured every 10 days using microcaliper, and tumor volume was calculated according to the following formula: tumor volume = (width2 × length)/2. The animals were sacrificed and tumors were excised after 30 days after injection. Tumor size was measured, and then the tumor was immediately frozen in liquid N2 for protein extraction.
Protein extraction of xenograft tumors
Tumor tissue (approximate 5 mg) frozen in liquid N2 was manually homogenized on ice, lysed in lysis buffer supplemented with protease inhibitors, and then incubated on ice for 2 h. The supernatants were cleared by centrifugation (12,000 rpm, 20 min, 4°C). Protein extracts were used for assessing expression of STIM1 protein in the tumor samples by Western blot which described above.
Data were expressed as the mean ± standard deviation (SD) of at least three independment experiments. The results were analyzed by Student’s t-test, and P < 0.05 was considered statistically significant.
All experimental research that is reported in the manuscript have been performed with the approval of Institutional Ethics Committee of Peking Union Medical College Hospital. Research carried out on humans be in compliance with the Helsinki Declaration, and all experimental research on animals follow internationally recognized guidelines.
Results and discussion
Expression of STIM1in human glioblastoma cell lines and HEK293 cell
To investigate the role of STIM1 in the malignant development of gliomas, we compared the expression levels of STIM1 protein in HEK293 cell and human glioblastomas cell lines in different transformation degree, as represented by U373 astrocytoma (WHO Grade III), U87 and U251 glioblastoma multiforme (WHO grade IV) lines by Western blot analysis. Of note, we chose HEK293 cell as a negative control of a non-tumor cell line for there was no normal glioma cell. As shown in Figure 1A, U251 cells, derived from a high-grade glioblastoma, showed higher expression of STIM1; therefore, U251 cells represent a reasonable cell culture system for experimental validations of data and were selected in the following loss of function experiments.
Lentivirus-mediated siRNA targeting STIM1 inhibited STIM1 expression in U251 cells
To address the question of whether STIM1 could serve as a therapeutic target for human glioblastoma, we employed RNA interference (RNAi) method in an attempt to inhibit the expression of STIM1 in U251 cells. The efficiency of lentivirus transduction in U251 cells was examined by fluorescent microscopy, and more than 90% of the cells were infected with si-STIM1 at 72 hrs post-transduction at MOI of 50 as indicated by the expression of GFP (Figure 1B). To determine the knock down efficiency of STIM1, quantitative real-time RT-PCR and Western blot analysis were performed. As shown in Figure 1C, mRNA level of STIM1 in cells that infected with si-STIM1 was significantly decreased about 89.7% ± 3.8% compared with that in cells infected with control-siRNA-expressing lentivirus (si-CTRL) 72 hrs after transduction (**P < 0.01). Additionally, Western blot analysis was also performed 72 hrs after lentivirus transduction. Expression of STIM1 protein was significantly reduced in the si-STIM1 group in comparison to si-CTRL group while little effect on the expression of Orai1, and expression of STIM2 was compensatorily risen to a certain extent. (Figure 1D). Totally, these results indicated that lentivirus-mediated siRNA efficiently and specifically suppressed STIM1 expression in U251 cells.
Suppression of STIM1 inhibited U251 cell proliferation
The effect of down-regulation of STIM1 on proliferation of glioblastoma cells in vitro was assessed by MTT assay, BrdU incorporation assay and colony formation assay. Firstly, the amount of cell proliferation was determined using the MTT assay once daily for 5 days. As shown in Figure 2A, STIM1 silencing inhibited U251 cell proliferation in a time-dependent manner. When compared with the si-CTRL group, the cell number in si-STIM1 group was significantly reduced by 43.6% ± 3.5% (**P < 0.01) at 5 days post-transduction. Besides, after performed TRPC entryway paralysor SKF9636 in U251 cell, the malignant proliferation of U251 cell was observably slow down compared with CTRL group. The cell proliferation of U373 and U87 cells were shown in Additional file 1: Figure S1A and S1B. They had the same tendency compare with U251 cell. Cell proliferative activity was then assessed by BrdU incorporation into cellular DNA. Figure 2B shows a significant decrease the growth rate of U252 cells in si-STIM1 group (33.6% ± 5.8%) in comparison to si-CTRL group (78.1% ± 4.0%) (** P < 0.01).
At the same time, results of double target RNAi U251 cell viability detected by MTT assay and direct cell counting method were shown in Additional file 2: Figure S2A and S2B. They had the same tendency. And then, we detected expression levels of STIM1 protein by Western blot which could be seen in Additional file 2: Figure S2C.
Furthermore, the colony formation capacity in U251,U373 cells which infected with si-STIM1 or si-CTRL lentivirus was estimated at 14 days after transduction. As shown in Figure 2C and 2D, the number of U251 cell colonies in the si-STIM1 group (19) was reduced by 63.8% ± 4.6% (**P < 0.01) in comparison to the si-CTRL group (48) . The colony formation capacity in U373 cells was also shown in Figure 2C and 2D.
Collectively, these results showed that knock down of STIM1 by lentivirus-mediated siRNA could inhibit U251 cell proliferation in vitro.
Suppression of STIM1 induced cell cycle arrest in G0/G1 phase and alterant expression levels of cell cycle-related genes in U251 cells
To further elucidate the growth suppression effect of si-STIM1 on U251 cells, we performed cell cycle distribution analysis by flow cytometry at 24, 48 and 72 hrs after transduction. As shown in Figure 3A, 3B and 3C, STIM1 knockdown induced cell cycle arrest in G0/G1 phase in U251 cells. When compared with the si-CTRL group, the percentage of G0/G1 phase in the si-STIM1 group was increased by 1.9% (*P < 0.05) at 48 hrs; what’s more, the percentage of G0/G1 phase in the si-STIM1 group was increased by 5.6% (*P < 0.05) at 72 hrs. The result demonstrate that STIM1 silencing may induce cell cycle arrest at G0/G1 phase and the effection of STIM1 on cell cycle does have time dependence.
We next performed real-time RT-PCR and Western blot analysis to assess the mRNA and protein levels of cell cycle-related molecules. After 72 hrs of transduction, RNAi-mediated STIM1 silencing induced upregulation of p21waf1/cip1 and downregulation of cyclin D1 and CDK4 simultaneously in U251 cells (Figure 4A and 4B). The results demonstrated that STIM1 may be involved in regulating the expression of cyclins-cyclin-dependent kinases (CDKs)-CDK inhibitors (CDKIs) in U251 cells.
Lentivirus-mediated si-STIM1 inhibited tumor growth in vivo
To determine whether STIM1 silencing could inhibit tumor development in vivo, lentivirus transduced U251 cells were subcutaneously injected into the right dorsal flank of the nude mice and tumor growth was evaluated. As shown in Figure 5A, the average growth rate of the ten si-STIM1 xenografts was reduced by 41.9% ± 5.7% (**P < 0.001, day 30) compare with control tumors (si-CTRL) as assessed by serial microcaliper measurements. si-STIM1 tumors that were resected on day 30 post-inoculation weighed 50% less than si-CTRL tumors (*P < 0.05) (Figure 5B). Representative photographs of mice in two groups (si-STIM1 and si-CTRL) and their transplanted tumors were shown in Figure 5C. Western blot analysis verified that STIM1 levels remained downregulation in the si-STIM1 transduced U251 xenografts in comparison to the control (Figure 5D). Thus, these results indicated that lentivirus-mediated gene silencing of STIM1 may be a promising therapeutic strategy for human glioblastoma.
SOCE, also known as capacitative Ca2+ entry, is thought to have an essential role in the regulation of contraction, cell proliferation, and apoptosis [23–25]. As a Ca2+ sensor in the ER, STIM1 is capable of triggering a cascade of reactions leading to SOCE activation , and involved in control of nontumorous cell proliferation [26–28]. Several studies have shown that STIM1 is overexpressed in human glioblastoma [15, 16], but the molecular mechanism was not identified. Its role in regulating cancer cell proliferation and progression may be indirect and dependent on other Ca2+ entry proteins. Recent study by Liu et al. shows that calcium release-activated calcium (CRAC) channels regulate glioblastoma cell proliferation. Both Orai1 and STIM1 knockdown induced sustained proliferation inhibition in glioma C6 cells by using siRNA technology, being the effect of Orai1 silencing more prominent than that of STIM1 silencing . Furthermore, Bomben and Sontheimer have recently shown that silencing the expression of TRPC1, a member of the family of TRPC channels also involved in SOCE, inhibits the proliferation of D54MG glioma cells and in vivo tumor growth .
In the present study, we found that STIM1 protein was expressed in human glioblastomas cell of different transformation degree, especially higher expressed in U251 cells that were derived from a high-grade glioblastoma; therefore, these phenomenon represent a reasonable cell culture system for STIM1 loss of function experiment. We employ lentivirus-mediated siRNA to suppress STIM1 expression in U251 cells. More than 90% of the cells were infected at MOI of 50 as indicated by the expression of GFP at 72 hrs post-transduction (Figure 1B). Both STIM1 mRNA and protein expression levels in U251 cells were downregulated (Figure 1C and 1D). Furthermore, knockdown of STIM1 inhibited U251 cell proliferation by inducing cell cycle arrest in G0/G1 phase in vitro, and this inhibition of proliferation would be in connection with damage of functional integrity of Ca2+ which induced by STIM1 knock-down (Figures 2 and 3). Through U251 xenograft model in nude mice, we found that STIM1 silencing also significantly affect tumor growth in vivo (Figure 4). Thus, these findings showed that STIM1 silencing resulted in changes in cell cycle progression and exhibited in vivo effects in tumorigenesis.
Deregulated cell cycle progression is one of the primary characteristics of cancer cells . Cell cycle progression involves sequential activation of CDKs whose association with corresponding regulatory cyclins is necessary for their activation [31, 32]. As a critical modulator of G1 to S transition, increased expression of Cyclin D1 in cancer cells resulted in an uncontrolled growth advantage. Cyclin D-CDK4/CDK6 and cyclin E-CDK2 complexes regulate cell cycle entry from G1 to S phase, phosphorylate and inactivate the retinoblastoma (Rb) protein. Upon phosphorylation, Rb dissociates from E2F family of transcription factors and allows for E2F-dependent transcription to occur . As shown in Figure 3C and 3D, STIM1 silencing in U251 cells resulted in a marked decrease in the expression of cyclin D1 and CDK4. On the other hand, the CDKIs p21 waf1/cip1 and p27 kip1 regulate the progression of cells in the G0/G1 phase of the cell cycle and induction of these proteins causes a blockade of the G1 to S transition, thereby resulting in a G0/G1 phase arrest of the cell cycle . The loss of CDKI in human cancers leads to uncontrolled cell proliferation which due to an increase in the levels of the CDK-cyclin complex . In present study, STIM1 silencing caused a marked increase in expression of p21 waf1/cip1 in U251 cells (Figure 3C and 3D). These observations suggest that STIM1 may play an important role in cell cycle progression of human glioblastoma by regulating the cyclins-CDKs-CDKIs expression.
The mechanisms linked to the inhibition of cell proliferation and tumor growth after STIM1 silencing were rather similar to our previous report which we show that RNAi-mediated silencing of the protein iASPP also results in G0/G1 cell cycle arrest in glioblastoma U251 cells, with concomitant changes in the expression of cyclin D1 and p21wafl/cip1. However, subsequent study of the signaling pathway which regulates STIM1 function in glioblastoma still needs to be elucidated.
In conclusion, we report that STIM1 is expressed in human glioma cell lines derived from a high-grade glioblastoma. RNAi-mediated gene silencing of STIM1 suppresses U251 cell growth both in vitro and in vivo, and blocks cell cycle progression at the G0/G1 phase. The anticancer effect of STIM1 silencing is likely mediated through the regulation of a large number of genes involved in cell cycle control, including p21Waf1/Cip1, cyclin D1 and CDK4. Thus, our findings illustrate the biological significance of STIM1 in tumorigenesis of glioma, and provide evidences that STIM1 may be a potential therapeutic target for human glioblastoma.
Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 2005, 109: 93-108. 10.1007/s00401-005-0991-y.
Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002, 359: 1011-1018.
Lawler SE, Peruzzi PP, Chiocca EA: Genetic strategies for brain tumor therapy. Cancer Gene Ther. 2006, 13: 225-233. 10.1038/sj.cgt.7700886.
Hendruschk S, Wiedemuth R, Aigner A, Topfer K, Cartellieri M, Martin D, Kirsch M, Ikonomidou C, Schackert G, Temme A: RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol. 2011, 13: 1074-1089. 10.1093/neuonc/nor098.
Yu F, Ng SS, Chow BK, Sze J, Lu G, Poon WS, Kung HF, Lin MC: Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol. 2011, 103: 187-195. 10.1007/s11060-010-0377-4.
Berridge MJ, Bootman MD, Roderick HL: Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003, 4: 517-529. 10.1038/nrm1155.
Berridge MJ, Lipp P, Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 2000, 1: 11-21.
Putney JW: A model for receptor-regulated calcium entry. Cell Calcium. 1986, 7: 1-12. 10.1016/0143-4160(86)90026-6.
Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell JE, Meyer T: STIM is a Ca2+ sensor essential for Ca2 + -store-depletion-triggered Ca2+ influx. Curr Biol. 2005, 15: 1235-1241. 10.1016/j.cub.2005.05.055.
Roos J, DiGregorio PJ, Yeromin AV, Ohlsen K, Lioudyno M, Zhang S, Safrina O, Kozak JA, Wagner SL, Cahalan MD: STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol. 2005, 169: 435-445. 10.1083/jcb.200502019.
Spassova MA, Soboloff J, He LP, Xu W, Dziadek MA, Gill DL: STIM1 has a plasma membrane role in the activation of store-operated Ca(2+) channels. Proc Natl Acad Sci USA. 2006, 103: 4040-4045. 10.1073/pnas.0510050103.
Sabbioni S, Barbanti-Brodano G, Croce CM, Negrini M: GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res. 1997, 57: 4493-4497.
Sabbioni S, Veronese A, Trubia M, Taramelli R, Barbanti-Brodano G, Croce CM, Negrini M: Exon structure and promoter identification of STIM1 (alias GOK), a human gene causing growth arrest of the human tumor cell lines G401 and RD. Cytogenet Cell Genet. 1999, 86: 214-218. 10.1159/000015341.
Yang S, Zhang JJ, Huang XY: Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009, 15: 124-134. 10.1016/j.ccr.2008.12.019.
Liu H, Hughes JD, Rollins S, Chen B, Perkins E: Calcium entry via ORAI1 regulates glioblastoma cell proliferation and apoptosis. Exp Mol Pathol. 2011, 91: 753-760. 10.1016/j.yexmp.2011.09.005.
Scrideli CA, Carlotti CG, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo SM: Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. J Neurooncol. 2008, 88: 281-291. 10.1007/s11060-008-9579-4.
Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, Chang HC, Tang MJ, Shen MR: Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci USA. 2011, 108: 15225-15230. 10.1073/pnas.1103315108.
Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q: Merlin is a potent inhibitor of glioma growth. Cancer Res. 2008, 68: 5733-5742. 10.1158/0008-5472.CAN-08-0190.
Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003, 33: 401-406. 10.1038/ng1117.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.
Nunez R: DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 2001, 3: 67-70.
Park KM, Trucillo M, Serban N, Cohen RA, Bolotina VM: Role of iPLA2 and store-operated channels in agonist-induced Ca2+ influx and constriction in cerebral, mesenteric, and carotid arteries. Am J Physiol Heart Circ Physiol. 2008, 294: H1183-H1187.
Weiss H, Amberger A, Widschwendter M, Margreiter R, Ofner D, Dietl P: Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer. 2001, 92: 877-882. 10.1002/ijc.1280.
Chiu WT, Tang MJ, Jao HC, Shen MR: Soft substrate up-regulates the interaction of STIM1 with store-operated Ca2+ channels that lead to normal epithelial cell apoptosis. Mol Biol Cell. 2008, 19: 2220-2230. 10.1091/mbc.E07-11-1170.
Zou JJ, Gao YD, Geng S, Yang J: Role of STIM1/Orai1-mediated store-operated Ca(2) entry in airway smooth muscle cell proliferation. J Appl Physiol. 2011, 110: 1256-1263. 10.1152/japplphysiol.01124.2010.
Kuang CY, Yu Y, Guo RW, Qian DH, Wang K, Den MY, Shi YK, Huang L: Silencing stromal interaction molecule 1 by RNA interference inhibits the proliferation and migration of endothelial progenitor cells. Biochem Biophys Res Commun. 2010, 398: 315-320. 10.1016/j.bbrc.2010.06.088.
El Boustany C, Katsogiannou M, Delcourt P, Dewailly E, Prevarskaya N, Borowiec AS, Capiod T: Differential roles of STIM1, STIM2 and Orai1 in the control of cell proliferation and SOCE amplitude in HEK293 cells. Cell Calcium. 2010, 47: 350-359. 10.1016/j.ceca.2010.01.006.
Bomben VC, Sontheimer H: Disruption of transient receptor potential canonical channel 1 causes incomplete cytokinesis and slows the growth of human malignant gliomas. Glia. 2010, 58: 1145-1156. 10.1002/glia.20994.
Grana X, Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995, 11: 211-219.
Schafer KA: The cell cycle: a review. Vet Pathol. 1998, 35: 461-478. 10.1177/030098589803500601.
Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000, 33: 261-274. 10.1046/j.1365-2184.2000.00191.x.
Massague J: G1 cell-cycle control and cancer. Nature. 2004, 432: 298-306. 10.1038/nature03094.
Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999, 287: 821-828. 10.1006/jmbi.1999.2640.
Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002, 1602: 73-87.
Li G, Wang R, Gao J, Deng K, Wei J, Wei Y: RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells. Mol Cell Biochem. 2011, 350: 193-200. 10.1007/s11010-010-0698-9.
The authors have no conflict of interests.
GL, ZZ and YW conceived, coordinated and designed the study, and contributed to the acquisition, analysis and interpretation of data and drafted the manuscript. RW, WM, YY, and JW performed the experiment and involved in drafting the article. YW accepts full responsibility for the work and/or the conduct of the study, had access to the data, and oversaw the decision to publish. All authors read and approved the final manuscript.
Guilin Li, Zhenxing Zhang contributed equally to this work.
Electronic supplementary material
Additional file 1: Figure S1: Effect of STIM1 silencing on U87 and U373 cell proliferation. (A) Cell proliferation of lentivirus-transduced U87 cell were measured by MTT assay once daily. (B) Cell proliferation of lentivirus-transduced U373 cell were measured by MTT assay once daily. Cell proliferation was expressed as the absorbance values. (TIFF 111 KB)
Additional file 2: Figure S2: Specific knockdown of STIM1 in U251 cells. Cell proliferation of double targets RNAi U251 cell were measured by MTT assay (A) and direct cell counting method (B) once daily. Cell proliferation was expressed as the absorbance values. (C) Western blot detecting for STIM1 in si-CTRL group and si-STIM1 group. (TIFF 182 KB)
About this article
Cite this article
Li, G., Zhang, Z., Wang, R. et al. Suppression of STIM1 inhibits human glioblastoma cell proliferation and induces G0/G1 phase arrest. J Exp Clin Cancer Res 32, 20 (2013). https://doi.org/10.1186/1756-9966-32-20
- Store-operated Ca2+ entry
- Stromal interacting molecule 1
- Cell cycle arrest
- Human glioblastoma